"10.1371_journal.pone.0055538","plos one","2013-01-31T00:00:00Z","Subhashini Jagu; Kihyuck Kwak; Balasubramanyam Karanam; Warner K Huh; Vijayarangam Damotharan; Sudha V Chivukula; Richard B S Roden","Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Oncology, Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America; Shantha Biotechnics Limited, Hyderabad, Andhra Pradesh, India","Conceived and designed the experiments: SJ RBSR. Performed the experiments: SJ KK BK. Analyzed the data: SJ WKH VD SVC RBSR. Contributed reagents/materials/analysis tools: KK RBSR. Wrote the paper: SJ WKH VD SVC RBSR.","The authors have the following interests. VD and SVC are employed by Shantha Biotechnics Limited. This study was partly funded by Sanofi Pasteur/Shantha Biotechnics and Public Health Service grants CA133749, CA118790, P50 CA098252. SJ and RBSR are co-inventors on L2 patents licensed to Shantha Biotechnics Ltd., GlaxoSmithKline, PaxVax, Inc. and Acambis, Inc. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. The relevant US patent application numbers and names are: 20090047301 Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies, 20100297144 Multitype HPV Peptide Compositions and Methods for Treatment or Prevention of Human Papillomavirus Infection.","2013","01","Subhashini Jagu","SJ",7,TRUE,2,3,5,5,TRUE,TRUE,FALSE,0,NA,FALSE
